AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded down 5% during mid-day trading on Thursday . The stock traded as low as $13.20 and last traded at $13.25. 797,989 shares traded hands during trading, a decline of 3% from the average session volume of 825,392 shares. The stock had previously closed at $13.95.

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated a “hold” rating and set a $21.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. B. Riley reiterated a “hold” rating and set a $16.00 price objective on shares of AMAG Pharmaceuticals in a research report on Tuesday. Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Morgan Stanley reduced their price objective on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, November 3rd. Finally, Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Wednesday, October 4th. Twelve analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $21.27.

The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. The company has a market capitalization of $467.57, a price-to-earnings ratio of -2.18 and a beta of 0.79.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. equities analysts predict that AMAG Pharmaceuticals, Inc. will post -4.17 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Fox Run Management L.L.C. purchased a new position in AMAG Pharmaceuticals during the fourth quarter worth $449,000. Schwab Charles Investment Management Inc. boosted its stake in AMAG Pharmaceuticals by 5.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 447,363 shares of the specialty pharmaceutical company’s stock worth $5,928,000 after buying an additional 22,488 shares during the period. Hikari Power Ltd boosted its stake in AMAG Pharmaceuticals by 14.3% during the fourth quarter. Hikari Power Ltd now owns 80,000 shares of the specialty pharmaceutical company’s stock worth $1,060,000 after buying an additional 10,000 shares during the period. GSA Capital Partners LLP boosted its stake in AMAG Pharmaceuticals by 43.3% during the third quarter. GSA Capital Partners LLP now owns 133,270 shares of the specialty pharmaceutical company’s stock worth $2,459,000 after buying an additional 40,270 shares during the period. Finally, Eii Capital Management Inc. boosted its stake in AMAG Pharmaceuticals by 41.5% during the third quarter. Eii Capital Management Inc. now owns 119,690 shares of the specialty pharmaceutical company’s stock worth $2,208,000 after buying an additional 35,090 shares during the period.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/amag-pharmaceuticals-amag-shares-down-5/1812927.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.